Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

The RESPLASH Study

NCT: NCT06880562 · NOT_YET_RECRUITING

NCT IDNCT06880562
StatusNOT_YET_RECRUITING
Start Date2026-12
Completion2027-12
SponsorTulane University (OTHER)
First posted
Last updated

Brief Summary

To assess the safety and effectiveness of renal artery denervation with subsequent splanchnic nerves denervation via catheter-based radiofrequency ablation in improving blood pressure and glycemic control in patients with resistant hypertension and type 2 diabetes.

Frequently Asked Questions

What is The RESPLASH Study?

The RESPLASH Study is a clinical trial registered under NCT06880562. Current status: NOT_YET_RECRUITING.

What is the status of NCT06880562?

The current status of NCT06880562 (The RESPLASH Study) is: NOT_YET_RECRUITING.

When did The RESPLASH Study start?

The RESPLASH Study started on 2026-12.

Related Devices

PMA P220023Ablation catheter, renal denervationRecor Medical, Inc. PMA P220026Ablation catheter, renal denervationMedtronic, Inc.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑